JP5976322B2 - テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体塩、その製造方法及び医薬用途 - Google Patents

テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体塩、その製造方法及び医薬用途 Download PDF

Info

Publication number
JP5976322B2
JP5976322B2 JP2011552307A JP2011552307A JP5976322B2 JP 5976322 B2 JP5976322 B2 JP 5976322B2 JP 2011552307 A JP2011552307 A JP 2011552307A JP 2011552307 A JP2011552307 A JP 2011552307A JP 5976322 B2 JP5976322 B2 JP 5976322B2
Authority
JP
Japan
Prior art keywords
salt
acid
imidazo
tetrahydro
trifluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011552307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519193A (ja
JP2012519193A5 (https=
Inventor
タン・ペンチョ
スン・ピャオヤン
ヤン・ファンロン
リャン・ジンドン
シェン・グァンユァン
ワン・ヤン
ファン・ジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of JP2012519193A publication Critical patent/JP2012519193A/ja
Publication of JP2012519193A5 publication Critical patent/JP2012519193A5/ja
Application granted granted Critical
Publication of JP5976322B2 publication Critical patent/JP5976322B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011552307A 2009-03-05 2010-03-03 テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体塩、その製造方法及び医薬用途 Expired - Fee Related JP5976322B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910047075A CN101824036A (zh) 2009-03-05 2009-03-05 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
CN200910047075.4 2009-03-05
PCT/CN2010/000257 WO2010099698A1 (zh) 2009-03-05 2010-03-03 四氢咪唑并[1,5-a]吡嗪衍生物的盐，其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
JP2012519193A JP2012519193A (ja) 2012-08-23
JP2012519193A5 JP2012519193A5 (https=) 2016-07-21
JP5976322B2 true JP5976322B2 (ja) 2016-08-23

Family

ID=42688223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011552307A Expired - Fee Related JP5976322B2 (ja) 2009-03-05 2010-03-03 テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体塩、その製造方法及び医薬用途

Country Status (12)

Country Link
US (1) US8518946B2 (https=)
EP (1) EP2404921B1 (https=)
JP (1) JP5976322B2 (https=)
KR (1) KR101731602B1 (https=)
CN (2) CN101824036A (https=)
AU (1) AU2010220722B2 (https=)
CA (1) CA2753862C (https=)
MX (1) MX2011009190A (https=)
RU (1) RU2523543C2 (https=)
UA (1) UA106225C2 (https=)
WO (1) WO2010099698A1 (https=)
ZA (1) ZA201107284B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899048B (zh) * 2009-05-27 2013-04-17 上海恒瑞医药有限公司 (R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐
CN103724352B (zh) * 2012-10-16 2017-11-28 江苏盛迪医药有限公司 一种dpp‑iv抑制剂的中间体、其制备方法和通过其制备dpp‑iv抑制剂的方法
CN103664962A (zh) * 2013-12-20 2014-03-26 南京华威医药科技开发有限公司 哌嗪类衍生物
CN103910734B (zh) * 2014-03-28 2016-01-13 南京华威医药科技开发有限公司 一种具有哌嗪结构的dpp-4抑制剂
US10189841B2 (en) 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
US11098058B2 (en) 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
SG11202002877RA (en) 2017-10-31 2020-04-29 Hoffmann La Roche Bicyclic sulfones and sulfoxides and methods of use thereof
JP7553450B2 (ja) * 2018-12-28 2024-09-18 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１を阻害するための組成物
CN113620957B (zh) * 2020-05-08 2022-04-19 盛世泰科生物医药技术(苏州)有限公司 一种胺甲基吡嗪类化合物的制备方法
CN113773323B (zh) * 2020-06-10 2023-05-12 江苏恒瑞医药股份有限公司 3r-氨基取代丁酰胺衍生物的制备方法
CN113880825B (zh) * 2020-07-01 2025-03-14 浙江海正药业股份有限公司 四氢异喹啉类衍生物的盐、其制备方法及其医药应用
JP2024504328A (ja) * 2021-01-21 2024-01-31 ザ スクリプス リサーチ インスティテュート 肺疾患の治療のための肺胞２型細胞増殖の小分子調節因子
CN114057751B (zh) * 2022-01-17 2022-04-12 盛世泰科生物医药技术(苏州)有限公司 一种dpp-iv抑制剂及其关键中间体的制备方法
CN115583935A (zh) * 2022-11-03 2023-01-10 浙江工业大学 一种4-(2,4,5-三氟苯基)-3-氧丁酸酯的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
CN101468988A (zh) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
KR101731602B1 (ko) 2017-04-28
CA2753862A1 (en) 2010-09-10
JP2012519193A (ja) 2012-08-23
WO2010099698A1 (zh) 2010-09-10
CN101824036A (zh) 2010-09-08
US20120065209A1 (en) 2012-03-15
CA2753862C (en) 2017-05-23
EP2404921A1 (en) 2012-01-11
HK1154574A1 (en) 2012-04-27
MX2011009190A (es) 2011-09-26
EP2404921A4 (en) 2012-08-15
CN102159578B (zh) 2013-04-10
ZA201107284B (en) 2012-12-27
AU2010220722B2 (en) 2015-05-07
AU2010220722A1 (en) 2011-10-27
UA106225C2 (ru) 2014-08-11
RU2011137858A (ru) 2013-04-10
KR20110132561A (ko) 2011-12-08
CN102159578A (zh) 2011-08-17
EP2404921B1 (en) 2017-11-22
RU2523543C2 (ru) 2014-07-20
AU2010220722A2 (en) 2011-11-03
US8518946B2 (en) 2013-08-27

Similar Documents

Publication Publication Date Title
JP5976322B2 (ja) テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体塩、その製造方法及び医薬用途
JP2012519193A5 (https=)
JP6637136B2 (ja) バルドキソロンメチルの２，２−ジフルオロプロピオンアミド誘導体、その多形体および使用方法
EP3983384B1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
US11203597B2 (en) Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing
RU2720488C2 (ru) Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия
EP4089102A1 (en) Modulators of sortilin activity
EP4079748A1 (en) Modulators of sortilin activity
KR20170033684A (ko) 리나글립틴 결정형 및 이의 제조방법
CN112739346A (zh) 大麻素及其用途
AU2018249237B2 (en) Substituted imidazole salt compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof
JP5661177B2 (ja) ヘキサヒドロピロロ［３，４−ｂ］ピロール誘導体、その製造方法及び用途
TWI522358B (zh) 四氫咪唑并〔１，５－ａ〕吡衍生物的鹽，其製備方法及其在醫藥上的應用
WO2008148279A1 (en) Cyclobutyl-fused pyrrolidine derivatives, their preparation methods and their medical use
HK1154574B (en) Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof
RU2819762C1 (ru) Соединение в качестве ингибитора циклинзависимой киназы 9 и его применение
AU2020274362B2 (en) Substituted fluorine-containing imidazole salt compound, preparation method therefor, pharmaceutical composition thereof and use thereof
EP4653442A1 (en) Polycyclic compound for treating neurological diseases and tumors
EP4655294A1 (en) Pyrazole derivstives as phd inhibitors
WO2026061488A1 (zh) 1,2,3-三氮唑类化合物及其作为apj受体激动剂的用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150109

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150227

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160720

R150 Certificate of patent or registration of utility model

Ref document number: 5976322

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

LAPS Cancellation because of no payment of annual fees